ClinicalTrials.gg
TerminatedNCT02188368Updated Nov 3, 2023

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

A Phase 2 interventional study of POM and Steroids in Multiple Myeloma, sponsored by Oncotherapeutics. Terminated at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-03.

Sponsored by Oncotherapeutics · Phase 2, Interventional, and Treatment

Why this study was terminated
Lack of enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 102 studies testing pomalidomide in Multiple Myeloma — 15 open to participants now, 39 under way, 9 of them phase 3. pomalidomide · Multiple Myeloma.

Enrollment
55th of 102
45 · median 50
Started
2014
with 10 others
Phase 2
55 of 102
9 open now
Registered
31st of 102
by date
Lead sponsor
4 of 102
Oncotherapeutics

Among the 102 studies testing pomalidomide in Multiple Myeloma, this one is the 55th largest by enrollment, is one of 11 that started in 2014, is one of 55 in phase 2, and was the 31st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 102 studies testing pomalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About pomalidomide

pomalidomide: first FDA approval 2013 (POMALYST), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies testing pomalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma (MM).

Pomalidomide (alone or in combination with dexamethasone) has been approved by the United States Food and Drug Administration (FDA) for the treatment of MM patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of their last therapy. However, the use of pomalidomide in combination with other drugs used to treat MM, such as chemotherapeutic agents and proteasome inhibitors, is currently being tested and is not approved. Pomalidomide is in the same drug class as thalidomide and lenalidomide. Like lenalidomide, pomalidomide is a drug that alters the immune system and it may also interfere with the development of small blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. The testing done with pomalidomide thus far has shown that it is well-tolerated and effective for subjects with MM both on its own and in combination with dexamethasone. Using another drug class, namely proteasome inhibitors, we have demonstrated that simply replacing a proteasome inhibitor with another in an established anti-myeloma treatment regimen can frequently overcome resistance regardless of the other agents that are part of the anti-myeloma regimen. Importantly, the toxicity profile of the new combinations closely resembled that of the proteasome inhibitor administered as a single agent. Based on this experience, we hypothesize that the replacement of lenalidomide with pomalidomide will yield similar results in a similar relapsed/refractory MM patient population.

Read the detailed description

This is a phase 2, multicenter, open-label and non-randomized study to evaluate the efficacy and safety of pomalidomide as a replacement for lenalidomide among MM patients who have failed lenalidomide-containing regimens that include more than steroids within 6 months of their last dose of lenalidomide. Pomalidomide will replace lenalidomide in a combination regimen containing an alkylating agent (cyclophosphamide), anthracycline (doxorubicin or PLD), proteasome inhibitor (bortezomib or carfilzomib) and/or a glucocorticosteroid (prednisone, dexamethasone or methylprednisolone). Pomalidomide will be administered on days 1-21 of a 28-day cycle, whereas other drugs (anthracyclines, proteasome inhibitors, steroids or alkylating agents except melphalan) will be administered using the same schedule(s), dose(s) and drug combination as the last lenalidomide-containing regimen that the patient received and failed. This study will enroll patients resistant to a lenalidomide-containing combination regimen as demonstrated by PD while being treated or that has relapsed within 6 months of the last dose of lenalidomide in their last lenalidomide-containing combination regimen or while on lenalidomide or lenalidomide and steroid maintenance therapy. Forty-five patients will be enrolled in the study.

The study consists of: 1) a screening period; 2) up to eight 28-day, treatment cycles; 3) a final assessment to occur 28 days after the end of the last treatment cycle; and 4) a follow-up period.

Subjects eligible for this study will receive treatment with study drug for a maximum of eight 28-day treatment cycles, depending on the schedule of their last lenalidomide-containing regimen. Subjects are to be treated to a maximum response (lowest level of paraprotein) plus 1 additional cycle, without exceeding a total of 8 cycles, or complete 8 cycles of therapy without progressing (PD).

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Pomalidomide
  • Lenalidomide refractory
  • multiple myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Has a diagnosis of MM based on standard criteria as follows:

    • Major criteria:

      1. plasmacytomas on tissue
      2. bone marrow plasmacytosis (greater than 30% plasma cells)
      3. monoclonal immunoglobulin (Ig) spike on serum electrophoresis IgG greater than 3.5 g/dL or IgA greater than 2.0 g/dL; kappa or lambda light chain excretion greater than 1 g/day on 24-hour urine protein electrophoresis
    • Minor criteria:

      1. bone marrow plasmacytosis (10% to 30% plasma cells)
      2. monoclonal immunoglobulin present but of lesser magnitude than given under major criteria
      3. lytic bone lesions
      4. normal IgM less than 50 mg/dL, IgA less than 100 mg/dL, or IgG less than 600 mg/dL
    • Any of the following sets of criteria will confirm the diagnosis of multiple myeloma:

      • any 2 of the major criteria
      • major criterion 1 plus minor criterion 2, 3, or 4
      • major criterion 3 plus minor criterion 1 or 3
      • minor criteria 1, 2, and 3, or 1, 2, and 4
  2. Currently has progressive MM that has while currently receiving or within 6 months of receiving the maximum tolerated dose of lenalidomide at the physician's discretion as part of a combination treatment that includes more than just in a 21-day or a 28-day cycle schedule. MM patients that are relapsed or have refractory disease, as defined below, are both eligible for enrollment provided they fulfill the other eligibility criteria:

    • Patients are refractory to a lenalidomide combination regimen, when they progress while currently receiving the lenalidomide combination treatment or within 8 weeks of its last dose.
    • Patients are considered relapsed, when they progress between 8 and 26- weeks from their last dose of lenalidomide as part of a lenalidomide-combination therapy that includes more than just steroids.
    • Prior treatment with four days or less of a total of 400 mg of prednisone (or an equivalent potency of another steroid) for MM will not be considered a regimen
  3. Currently has MM with , defined as:

    • a monoclonal immunoglobulin spike on serum electrophoresis of at least 0.5 g/dL and/or
    • urine monoclonal protein levels of at least 200 mg/24 hours
    • for patients without measurable serum and urine M-protein levels, an abnormal free light chain ratio (normal value: 0.26 - 1.65)
    • Serum free light chain (SFLC) > 100 mg/L (involved light chain) and abnormal ƙ/λ ratio
  4. Patients with previous clotting or thrombotic events must be able to take aspirin (acetylsalicylic acid, ASA) at 81 or 325 mg /daily as prophylactic anticoagulation (subjects intolerant to ASA may use warfarin or low molecular weight heparin) and/or antithrombotic agents.

Key Exclusion Criteria:

  1. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes (POEMS) syndrome
  2. Plasma cell leukemia
  3. Primary amyloidosis
  4. Non-hematologic within the past 5 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas
  5. Impaired cardiac function or cardiac diseases, including myocardial infarction within 6 months prior to enrollment, (NYHA) Class II or greater heart failure, uncontrolled angina, clinically significant pericardial disease, severe uncontrolled ventricular arrhythmias, echocardiogram or multigated acquisition scan () evidence of left ventricular ejection fraction (LVEF) below institutional normal within 28 days prior to enrollment, electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any abnormality at Screening has to be documented by the investigator as not medically relevant.
  6. Received the following prior therapy:

    • Pomalidomide
    • Lenalidomide alone or in combination with steroids in their last treatment regimen. Interim therapy not containing lenalidomide between their last lenalidomide-containing regimen and the start of the trial.
    • A melphalan-containing regimen as the immediate
    • Chemotherapy within 3 weeks of study drugs (6 weeks for nitrosoureas)
    • Corticosteroids (>10 mg /daily prednisone or equivalent) within 3 weeks of study drugs
    • Immunotherapy or antibody therapy as well as thalidomide, lenalidomide, arsenic trioxide or bortezomib within 21 days before study drugs
    • Extensive radiation therapy within 28 days before study drugs. Receipt of localized radiation therapy does not preclude enrollment.
    • Use of any other experimental drug or therapy within 28 days of study drugs
  7. Known to compounds of similar chemical or biological composition to thalidomide and lenalidomide.
  8. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    A: POM 4mg+Steroids+(CFZ, BTZ, CY or CLA)

    POM 4 mg PO days 1-21 Steroids at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject). BTZ (bortezomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject). CFZ (carfilzomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject). CLA (clarithromycin) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject). CY (cyclophosphamide) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).

    Drug: POM · Drug: Steroids · Drug: CFZ · Drug: BTZ · Drug: CLA · Drug: CY

  • Experimental
    B: POM 3mg+PLD with or without steroids

    POM 3 mg PO days 1-21 Steroids (if the patient had received them) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject). PLD at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).

    Drug: POM · Drug: Steroids · Drug: PLD

  • Experimental
    C: POM MTD + other drugs

    Phase 1: POM at escalating doses of 2 mg (Cycle 1), 3 mg (Cycle 2) or 4 mg (Cycle 3+) All other agents at the same dose and on the same days as the patients were receiving them in the lenalidomide-containing regimen they had failed Phase 2: POM at the MTD All other agents, at the same dose and on the same days as phase 1

    Drug: POM

Interventions

  • DrugPOM

    Also known as: Pomalidomide, Pomalyst, Actimid, CC-4047

  • Also known as: Dexamethasone, prednisone, methyprednisolone

  • DrugPLD

    Also known as: Pegylated liposomal doxirrubicin

  • DrugCFZ

    Also known as: Carfilzomib, Kyprolis

  • DrugBTZ

    Also known as: Bortezomib, Velcade

  • DrugCLA

    Also known as: Clarithromycin

  • DrugCY

    Also known as: Cyclophosphamide

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    MTD will be determined for any ≥ three-drug combinations other than: bortezomib + steroids + lenalidomide; carfilzomib + steroids + lenalidomide; clarithromycin + steroids + lenalidomide; cyclophosphamide + steroids + lenalidomide pegylated liposomal doxorubicin (PLD) + lenalidomide with or without steroids

    Time frame: Cycles 1-3 for selected regimens (up to 3 months)

  2. Number of subjects with adverse events

    Adverse events will be graded via the Common Terminology Criteria for Adverse Events (CTCAE) v 4.03 criteria.

    Time frame: up to 36 months

  3. Overall Response Rate

    Overall response rate (ORR): complete response (CR)+ very good partial response (VGPR) + partial response (PR)

    Time frame: up to 36 months

  4. Clinical Benefit Rate (CBR)

    CBR=ORR + minor response (MR)

    Time frame: up to 36 months

Secondary outcomes

  1. Time to Progression

    The time from the initiation of therapy to progressive disease

    Time frame: time from initiation of therapy to progressive disease (assessed at least over 36 months)

  2. Progression-free survival (PFS)

    Time from initiation of therapy to progressive disease or death from any cause, whichever occurs first

    Time frame: time from initiation of therapy to progressive disease or death from any cause, whichever comes first (assessed at least over 36 months)

  3. Time to first response (TTP)

    time from initiation of therapy to the first evidence of a confirmed response

    Time frame: time from initiation of therapy to the first evidence of a confirmed response (up to 36 months)

  4. Duration of response (DOR)

    time from the first response (\> PR) to progressive disease

    Time frame: time from the first response (> PR) to progressive disease (assessed at least over 36 months)

  5. Overall survival (OS)

    time from initiation of therapy to death from any cause or last follow-up visit

    Time frame: time from initiation of therapy to death from any cause or last follow-up visit (assessed at least over 36 months).

07

Study locations

12 sites
  • California Cancer Associates for Research & Excellence (cCARE)
    Encinitas, California 92024, United States
  • Compassionate Care Research Group
    Fountain Valley, California 92708, United States
  • Comprehensive Cancer Center at Desert Regional Medical Center
    Palm Springs, California 92262, United States
  • Inland Hematology Oncology Medical Group, Inc
    San Bernardino, California 92404, United States
  • Wellness Oncology and Hematology
    West Hills, California 91307, United States
  • James R. Berenson, MD, Inc.
    West Hollywood, California 90069, United States
  • VA Sierra Nevada
    Reno, Nevada 89502, United States
  • San Juan Oncology Associates
    Farmington, New Mexico 87401, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Rapid City Regional Hospital
    Rapid City, South Dakota 57701, United States
  • Wellmont Medical Associates Oncology and Hematology
    Kingsport, Tennessee 37660, United States
  • Vista Oncology
    Olympia, Washington 98502, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2014 to primary completion in Oct 2020, 75 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2014
First posted
Jul 11, 2014
StartActual
Jul 7, 2014
Primary completionActual
Oct 23, 2020
CompletionActual
Oct 23, 2020
Last update
Nov 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02188368
Lead sponsor
Oncotherapeutics
Collaborators
Celgene Corporation
Responsible party
Sponsor
First posted
Jul 11, 2014
Start date
Jul 7, 2014
Primary completion
Oct 23, 2020
Completion
Oct 23, 2020
Last update
Nov 3, 2023

Study contacts

James R Berenson, MD
principal investigator · James R. Berenson MD, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pomalidomide

Start the discussion